Related Experiment Videos
Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain
1Oncology Department, Novartis, Basle, Switzerland.
Abstract:
p53 is very often mutated in human cancers. The majority of alterations are missense mutations located within the DNA-binding domain of the protein. Many reports have characterized such mutant proteins. Little is known, however, about the properties of proteins that have a missense mutation outside this domain. We investigated here the properties of 8 mutant proteins identified in human tumors as having a missense mutation in the tetramerization domain. The Arg342Gln, Glu349Asp and Gln354Arg proteins behaved like wild-type both in vitro and in cells. Two mutants, Arg342Pro and Leu344Pro, were inactive in all assays. Finally, the 3 mutant proteins Leu330His, Arg337Cys and Arg337Leu, which are inactive in vitro, showed no activity at low expression levels in cells but became active at higher expression levels. Our results reveal new phenotypes for p53 mutants and suggest that sequencing of the p53 gene from patients with tumors should be extended to exons 9 and 10 in clinical investigations.
Insights
Mutations in the p53 tumor suppressor protein outside its DNA-binding domain can alter its function. This study characterizes novel p53 mutant phenotypes, suggesting expanded genetic testing for cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p53 tumor suppressor protein is frequently mutated in human cancers.
- Most known p53 mutations occur in the DNA-binding domain, with limited characterization of mutations outside this region.
Purpose of the Study:
- To investigate the functional properties of p53 mutants with missense mutations in the tetramerization domain.
- To identify novel p53 mutant phenotypes and their implications for cancer diagnostics.
Main Methods:
- In vitro biochemical assays to assess p53 protein activity.
- Cell-based assays to evaluate the function of p53 mutants at varying expression levels.
Main Results:
- Three mutants (Arg342Gln, Glu349Asp, Gln354Arg) exhibited wild-type-like behavior.
- Two mutants (Arg342Pro, Leu344Pro) were completely inactive.
- Three mutants (Leu330His, Arg337Cys, Arg337Leu) showed expression-dependent activity in cells.
Conclusions:
- Missense mutations in the p53 tetramerization domain can lead to diverse functional outcomes, including wild-type-like activity, complete inactivation, or expression-dependent activity.
- These findings highlight the importance of analyzing p53 mutations beyond the DNA-binding domain.
- Expanded sequencing of p53 exons 9 and 10 is recommended for clinical cancer investigations.